Rainier Rehab Logo
Editorial illustration of a row of tall pale panels with one narrow gap between them, a thin…
November 18, 20268 min read

A Nursing Home Refused Her Because She Took Methadone. Twelve Companies Just Agreed to Stop.

The woman in Westmoreland County had been taking methadone for twenty years, prescribed by a physician, for chronic pain from fibromyalgia and Raynaud's syndrome. Then she fell at home and broke her hip. She needed rehabilitation, the kind that happens in a nursing home bed over weeks, not in a hospital corridor over days.

According to a complaint her daughter filed with the Pennsylvania Office of Attorney General in 2024, it took two hospitalizations to establish the pattern. Both times, the hospital tried to transfer her to a long-term rehabilitative facility. Both times, multiple facilities declined to take her. The reason given, in substance, was the medication.

On Monday, Attorney General Dave Sunday announced that twelve companies operating more than 200 nursing homes and other long-term care facilities have signed agreements to admit and accommodate prospective residents who take opioids or other medications to treat a disability — disabling pain, or opioid use disorder treated with medication. The commitments bind the companies' Pennsylvania facilities, and for those headquartered in the Commonwealth, their facilities nationwide.

What the companies agreed to is narrow and specific. They will assess prospective residents individually instead of automatically denying admission because of a medication on the resident's list. The standard comes from the Americans with Disabilities Act and the Pennsylvania Human Relations Act, both of which prohibit disability discrimination in covered public accommodations. Federal guidance is unusually direct on this point: the Department of Justice's own explainer on opioid use disorder walks through the exact scenario, describing a skilled nursing facility that refuses a patient because the patient takes doctor-prescribed medication for opioid use disorder, and concluding that "the facility's exclusion of patients based on their OUD would violate the ADA."

Individualized assessment, and the two doors out of it

The ADA framework the attorney general's office applied does not require a facility to accept every applicant. It requires the facility to look at the individual. A blanket ban on a class of medication is the thing the law disfavors, because it substitutes a policy for an assessment. What a facility may do instead is evaluate whether this particular patient, with this particular dose, this particular medical history, and this particular level of nursing need, can be served — and whether accommodating them would pose a direct safety threat or fundamentally alter the services the facility provides.

Those two exceptions are where the real arguments will happen. Facilities that refuse patients on opioids routinely cite fall risk and liability. The attorney general's announcement names the same concern implicitly by insisting on individual evaluation rather than category exclusion. The clinical literature does not support a blanket rule: methadone and buprenorphine are associated with sedation and, at high doses or in combination with other sedatives, with respiratory risk, which is a nursing supervision question and not a reason to exclude an entire diagnostic group from rehabilitation.

Civil rights enforcement in this area has been slow and complaint-driven. The Pennsylvania matter was handled by Deputy Attorney General Kevin Bendesky in the Civil Rights Enforcement Section, under Chief Deputy Attorney General Corbett Anderson. It moved because one daughter in Westmoreland County wrote a letter about her mother.

The twelve companies

The office published the list of providers making the commitments. It includes Care Realty LLC, which operates as CareOne; Communities at Indian Haven; Concordia Lutheran Ministries; GBK Eight, which purchased facilities from Guardian Healthcare; HCF Management; Kadima Healthcare; Oakdale Seniors Alliance; Quest Healthcare Development; Saber Healthcare Group; Select Medical Corporation; the University of Pittsburgh Medical Center; and WeCare Centers.

That is a meaningful slice of the Pennsylvania industry but not the whole of it. The state licenses hundreds of nursing facilities, and the agreements cover 200-plus. Nothing in the announcement suggests the remaining operators were investigated, and nothing requires them to change a policy. The commitment is an assurance of voluntary compliance, a settlement instrument that typically carries no admission of wrongdoing and no civil penalty; its force is that a breach gives the attorney general a documented basis to sue.

One detail in the public record is worth flagging for families: the file the office published with the company list is dated September 1, 2026, roughly two and a half months before the announcement. Whatever the internal timeline, the commitments were papered before they were publicized, which means facilities operating under them have had since late summer to change their intake practices.

What the Baltimore data shows about who gets turned away

The strongest evidence that this is a system problem rather than a handful of bad actors comes from a 2024 study in the Journal of Hospital Medicine, and its details are more useful than its headline.

Researchers led by Ifedayo Kuye at Johns Hopkins examined 6,043 hospitalizations with skilled nursing facility referrals at two academic hospitals in Baltimore in 2019. Of those, 603 involved patients with opioid use disorder. The patients with OUD needed more attempts to place: 8.9 referrals sent on average, against 5.6 for patients without OUD. They were accepted less often: 31.3 percent of referrals, against 46.9 percent. And they were less likely to leave the hospital to a nursing facility at all, 65.6 percent against 70.3 percent.

The subanalysis is the part that should shape how this Pennsylvania agreement is read. The reduced acceptance rate was driven by two groups: patients discharged without any medication for opioid use disorder, and patients on methadone. Patients discharged on buprenorphine were accepted at the same rate as patients without OUD.

Read plainly, facilities were not refusing "opioid patients." They were refusing patients whose opioid exposure came with unresolved clinical uncertainty — no covering prescriber, no clear plan — and they were refusing the one medication that a nursing home cannot simply continue.

The buprenorphine exception

That distinction has a consequence for policy that the announcement does not draw out. A discharge plan that guarantees a buprenorphine prescriber and a documented maintenance plan is, on this evidence, the most effective single thing a hospital can do to get an OUD patient into a rehab bed. An antidiscrimination agreement changes the default answer from no to maybe. A prescribing plan changes the clinical facts the assessment is about.

Why methadone is the hard case

Methadone for opioid use disorder is not dispensed like other opioids. Federal rules at 42 CFR Part 8 restrict it for that indication to certified opioid treatment programs, which is why the medication arrives with a daily-visit structure attached. A nursing home is not an OTP. Admitting a patient maintained on methadone therefore creates an operational obligation the facility has to solve — arranging transport to a program every day, or coordinating a transfer of care to a prescriber who can manage a transition.

That structural fact sits underneath a legal one, and the two get conflated in practice. A facility can tell itself it is declining for logistics and tell the family it is declining for safety.

The logistics nobody signed for

The Pennsylvania agreements address the legal question, not the logistical one. Whether a facility that signs actually admits methadone patients will depend on whether it has built the transport and prescriber arrangements, and no part of the announcement requires it to demonstrate that in advance.

There is also the matter of medication-assisted treatment being widely misunderstood inside long-term care, where the culture of opioid caution after a decade of prescribing crackdowns has hardened into blanket rules. Nursing homes have spent years reducing their own opioid prescribing; those same instincts, applied to a patient whose methadone is the treatment rather than the problem, produce exactly the refusals the attorney general investigated.

What the agreements do not do

They do not create a bed registry, a reporting requirement, or any public accounting of how many patients on methadone are admitted next year versus this year. There is no monitoring mechanism in the announcement and no deadline by which facilities must show changed practice. Families who are turned away will still have to prove what happened.

They also do not resolve the case of the woman in Westmoreland County in any public way. The announcement describes her situation as the origin of the investigation and says nothing about where she went, whether she received rehabilitation, or what it cost her family to find it. Her daughter's complaint is the entire documentary trace of an experience that the Baltimore data suggests is routine.

What a family can do at the admissions desk

For families facing this now, the practical sequence is worth writing down. Ask the admissions office for its policy on prescribed medications in writing, because a written blanket exclusion is the evidence an investigator needs and an oral one is not. Ask specifically whether the facility will conduct an individualized assessment and what information it needs to do so. If the answer is that the facility does not accept methadone or buprenorphine patients as a category, that is the sentence to put in a complaint to the Pennsylvania attorney general's Civil Rights Enforcement Section, or to the Department of Justice, which accepts ADA complaints from individuals and can also pursue pattern cases.

The Pennsylvania agreements are, in the end, twelve companies deciding that the paperwork of individual assessment is cheaper than the risk of a civil rights case. That is how most disability access gets built in this country: not by a ruling, but by an enforcement office making the alternative expensive. The 200-plus facilities that signed are now on record. The ones that did not sign are the ones to watch.

RR
Rainier Rehab Editorial Team

Editorial Board

LADC, LCPC, CASAC

The Rainier Rehab editorial team consists of licensed addiction counselors, healthcare journalists, and recovery advocates dedicated to providing accurate, evidence-based information about substance abuse treatment and rehabilitation.

Related Articles